Revenue and Accounts Receivable Credit Concentration (Tables)

6 Months Ended

Jun. 30, 2022

Revenue from Contract with Customer [Abstract]

Summary of Revenue

Revenues consisted of the following (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Diagnostic tests	$	10,206	$	10,838	$	15,839	$	38,033
Services		744		1,047		1,659		2,718
Total revenue	$	10,950	$	11,885	$	17,498	$	40,751

Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers

The Company’s customers in excess of 10% of total revenue both pertain to our COVID-19 diagnostic testing services, and their related revenue as a percentage of total revenue were as follows:

	Three Months Ended June 30,						Six Months Ended June 30,
	2022			2021			2022			2021
The State of Colorado		22	%		—			16	%		—
The Big Ten Conference		—			40	%		—			53	%

The Company’s third-party payors and other customers in excess of 10% of accounts receivable, and their related accounts receivable as a percentage of total accounts receivable were as follows:

	As of
	June 30, 2022			December 31, 2021
The State of Colorado		27	%		—
Medicare		26	%		30	%
Janssen Research and Development, LLC		11	%		14	%
LabCorp DD (formerly Covance)		4	%		11	%